NewLimit

Develops epigenetic reprogramming therapies that aim to restore youthful function to aging cells, starting with the liver and immune system.

View on the globe

$565MEquity raised in 2025–20262025 $130M · 2026 $435M · 2 equity rounds
$605MEquity raised, all time3 equity rounds on record
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 3 rounds from 16 May 2023 to 2 Jun 2026, $605M equity disclosed.16 May 2023: Series A, $40M; 6 May 2025: Series B, $130M; 2 Jun 2026: Series C, $435M$10M$30M$100M$300M$1B202420252026Equity round2 Jun 2026 · Series C · $435M · led by Founders Fund6 May 2025 · Series B · $130M · led by Kleiner Perkins16 May 2023 · Series A · $40MSeries C · $435MSeries B · $130MSeries A · $40M
Funding history: 3 rounds from 16 May 2023 to 2 Jun 2026, $605M equity disclosed.16 May 2023: Series A, $40M; 6 May 2025: Series B, $130M; 2 Jun 2026: Series C, $435M$10M$30M$100M$300M$1B202420252026Equity round2 Jun 2026 · Series C · $435M · led by Founders Fund6 May 2025 · Series B · $130M · led by Kleiner Perkins16 May 2023 · Series A · $40M$435M$130M$40M

Funding history 3 rounds · 4 sources · newest first

  1. Series C
    Amount$435M
    Post-money—
    ✓ Confirmed
    Lead
    Founders Fund
    Also
    Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract Ventures, Nat Friedman, Daniel Gross, Valor Equity Partners, Eli Lilly, Human Capital
    Note
    Valuation not stated. BioSpace dates the round June 3; the company post is dated June 2.
    Sources
  2. Series B
    Amount$130M
    Post-money—
    ◔ Reported
    Lead
    Kleiner Perkins
    Also
    Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension, Elad Gil, Garry Tan, Patrick Collison
    Sources
  3. Series A
    Amount$40M
    Post-money—
    ◔ Reported
    Also
    Dimension, Kleiner Perkins, Founders Fund, Fred Ehrsam, Garry Tan, Elad Gil
    Note
    No lead investor named in the source.
    Sources

Investors 17

  • Founders Fund3
  • Kleiner Perkins3
  • Daniel Gross2
  • Dimension2
  • Elad Gil2
  • Garry Tan2
  • Nat Friedman2
  • Abstract Ventures
  • Eli Lilly
  • Fred Ehrsam
  • Greenoaks
  • Human Capital
  • Khosla Ventures
  • Patrick Collison
  • Quiet Capital
  • Thrive Capital
  • Valor Equity Partners

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the South San Francisco hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. NewLimit and its logo are trademarks of their owners, used here for identification only.